Andrew Buchanan PhD FRSC University of Oxford

2023-04-03 22:04

Andrew Buchanan PhD FRSC

1st degree connection1st
Caring for today's patients, by making tomorrow's medicines better & faster together; a positive disrupter;biblical ?; Opinions are mine & not corporate

University of Oxford

Cambridge, England, United Kingdom Contact info

500+ connections

Martin Hornshaw and Anne Tecson are mutual connectionsMartin Hornshaw and Anne Tecson are mutual connections
Message
More

HighlightsHighlights

[Event logo]
In-Person Pistoia Alliance Annual Spring Conference for PA MembersIn-Person Pistoia Alliance Annual Spring Conference for PA Members
Andrew is attending this event in London, EnglandAndrew is attending this event in London, England

AboutAbout

Over 20 years experience (CaT,MedI,AZ) as a bench scientist, team leader, project leader or mentor. Doing biologics pipeline delivery (for Oncology & CVRM) and related technology development. A very experienced and successful multidisciplinary team leader. Contributing to >20 FTiH molecules, 5 in phase 1, 6 in phase 2, 1 in phase 3 and 3 are marketed medicines. Highlights include IMFINZI, MEDI2452, MEDI6570, AZD3427 & AZD9592.

Passionate about partnering with others, who have different domain expertise, to drive the innovation need to bring new medicines for all.

Special interest in innovation, in rank order:
1. Computational‍machine learning ?for better biologics drugs
2. drugs that can Reach the tissue, Retain in the tissue, Release for nano-medicines (ADCs)
3. Reducing ADC toxicity for patients
4. Medicines for Low & Medium Income Countries
5. Re-entering the holy grail of oral delivery of Biologics

Currently supervise 5 postdoctoral scientists at LMB, Cam Uni and Gothenburg

Awards:
2022 Oncology patent of the year
2021 CEO award for Augmented Drug Design, leveraging data and AI
2020 Science Star for tissue targeting
2020 Fellow Royal Society of Chemistry
2015 GMD award for PB2452
2013 CEO award for MEDI4166 innovative science
2005 Top Young British Scientists Commendation Award at House of Commons

35+ patents and original papers Over 20 years experience (CaT,MedI,AZ) as a bench scientist, team leader, project leader or mentor. Doing biologics pipeline delivery (for Oncology & CVRM) and related technology development. A very experienced and successful multidisciplinary team leader. Contributing to >20 FTiH molecules, 5 in phase 1, 6 in phase 2, 1 in phase 3 and 3 are marketed medicines. Highlights include IMFINZI, MEDI2452, MEDI6570, AZD3427 & AZD9592. Passionate about partnering with others, who have different domain expertise, to drive the innovation need to bring new medicines for all. Special interest in innovation, in rank order: 1. Computational‍machine learning ?for better biologics drugs 2. drugs that can Reach the tissue, Retain in the tissue, Release for nano-medicines (ADCs) 3. Reducing ADC toxicity for patients 4. Medicines for Low & Medium Income Countries 5. Re-entering the holy grail of oral delivery of Biologics Currently supervise 5 postdoctoral scientists at LMB, Cam Uni and Gothenburg Awards: 2022 Oncology patent of the year 2021 CEO award for Augmented Drug Design, leveraging data and AI 2020 Science Star for tissue targeting 2020 Fellow Royal Society of Chemistry 2015 GMD award for PB2452 2013 CEO award for MEDI4166 innovative science 2005 Top Young British Scientists Commendation Award at House of Commons 35+ patents and original papers

ActivityActivity

1,377 followers1,377 followers

PostsCommentsImages

Andrew Buchanan PhD FRSC posted this • 3d3d
Want to come work at the MRC Laboratory of Molecular Biology (LMB) with Harvey and me as an AstraZeneca #bluesky postdoc? Here’s a great opportunity to follow on from David Paul and build off his Nature Comms paper https://rdcu.be/c8SAF. It’s an opportunity to make new fundamental biological insights, from which we just might be able to make medicines one day. We need bright colleagues, with technical excellence, insight and great communication skills. For background on the LMB AZ Blusky scheme see https://lnkd.in/eX7MVtBq #opportunity #postdocposition #funatwork…show more
View Vacancy -- Postdoctoral Scientist - Neurobiology - Harvey McMahon - LMB 2114
mrc.tal.net • 2 min read

[like] [support] 14

Andrew Buchanan PhD FRSC reposted this • 1w1w
Great opportunity to target a new kind of pharmacology. Should be fascinating fun making this kind of targeted CT medicine.
Senior Scientist – Cell Therapy
astrazeneca.wd3.myworkdayjobs.com • 5 min read

[like] 8

Andrew Buchanan PhD FRSC reposted this • 3w3w
These postdocs have been brilliant. Watch their publication records. Wholly commend this role with Ola Engkvist, even though it’s focus is small not large molecule application

[like] 8

Show all activity

ExperienceExperience

[AstraZeneca logo]
AstraZenecaAstraZeneca
4 yrs 3 mos4 yrs 3 mos

Principal ScientistPrincipal Scientist
Full-timeFull-timeOct 2022 - Present · 7 mosOct 2022 - Present · 7 mosCambridgeshire, England, United KingdomCambridgeshire, England, United Kingdom

Multidisciplinary matrix team leader. Innovative scientist in biologics discovery. Looking for hard problems to solve.Multidisciplinary matrix team leader. Innovative scientist in biologics discovery. Looking for hard problems to solve.

Skills: People Development · People Management · Engaging People · Interpersonal Skills · Young PeopleSkills: People Development · People Management · Engaging People · Interpersonal Skills · Young People

Off sick due to MH breadownOff sick due to MH breadown
Full-timeFull-timeMay 2021 - Sep 2022 · 1 yr 5 mosMay 2021 - Sep 2022 · 1 yr 5 mosCambridge, England, United KingdomCambridge, England, United Kingdom

Now reformed and learnt a lot personally and professionally. It’s all about people and who to trustNow reformed and learnt a lot personally and professionally. It’s all about people and who to trust

Skills: People Development · TeamworkSkills: People Development · Teamwork

Senior DirectorSenior Director
Full-timeFull-timeJan 2021 - Jun 2022 · 1 yr 6 mosJan 2021 - Jun 2022 · 1 yr 6 mosCambridge, England, United Kingdom · On-siteCambridge, England, United Kingdom · On-site

Responsibility included CVRM Research Board, Targeting tech, Peptide tech & Machine Learning Computational Design strategyResponsibility included CVRM Research Board, Targeting tech, Peptide tech & Machine Learning Computational Design strategy

Show all 4 experiences
[MedImmune logo]
Senior to Principal ScientistSenior to Principal Scientist
MedImmuneMedImmuneJun 2007 - Dec 2020 · 13 yrs 7 mosJun 2007 - Dec 2020 · 13 yrs 7 mosCambridge, United KingdomCambridge, United Kingdom

Antibody Discovery and Protein Engineering
Project leadership in R&D
Focus on diabetes, obesity, cardiovascular for 8 years; oncology for 6 yearsAntibody Discovery and Protein Engineering Project leadership in R&D Focus on diabetes, obesity, cardiovascular for 8 years; oncology for 6 years…see more

Skills: People Development · People Management · Engaging People · Interpersonal SkillsSkills: People Development · People Management · Engaging People · Interpersonal Skills

Cambridge Antibody Technology logo
Research to Senior ScientistResearch to Senior Scientist
Cambridge Antibody Technology · Full-timeCambridge Antibody Technology · Full-time2001 - 2007 · 6 yrs2001 - 2007 · 6 yrsCambridge, England, United KingdomCambridge, England, United Kingdom

All things mAb, 4 helix bundles, peptide lead optimisation. Oncology focus…delivered Imfinzi All things mAb, 4 helix bundles, peptide lead optimisation. Oncology focus…delivered Imfinzi

Skills: Engaging People · Interpersonal SkillsSkills: Engaging People · Interpersonal Skills

[Monsanto Company logo]
Research ScientistResearch Scientist
MonsantoMonsanto2000 - 2001 · 1 yr2000 - 2001 · 1 yrCambridge, United KingdomCambridge, United Kingdom

Molecular geneticsMolecular genetics

Skills: Engaging People · Interpersonal SkillsSkills: Engaging People · Interpersonal Skills

EducationEducation

[University of Oxford logo]
University of OxfordUniversity of Oxford
Bachelor of Arts (BA), Biology, GeneralBachelor of Arts (BA), Biology, General1991 - 19941991 - 1994
[University of Birmingham logo]
University of BirminghamUniversity of Birmingham
Master of Science - MS, GeneticsMaster of Science - MS, Genetics1995 - 19961995 - 1996
[University of Bath logo]
University of BathUniversity of Bath
PhD, Molecular Genetics of Oil Palm disease resistancePhD, Molecular Genetics of Oil Palm disease resistance1996 - 19991996 - 1999

Skills: Engaging PeopleSkills: Engaging People

VolunteeringVolunteering

[American Association of Pharmaceutical Scientists (AAPS) | @aapscomms logo]
Community VolunteerCommunity Volunteer
American Association of Pharmaceutical Scientists (AAPS) | @aapscommsAmerican Association of Pharmaceutical Scientists (AAPS) | @aapscommsScience and TechnologyScience and Technology

2023 May AAPS National Biotechnology Conference: Abstract Screening
2023 Oct AAPS Pharm Sci 360: Abstract Screening2023 May AAPS National Biotechnology Conference: Abstract Screening 2023 Oct AAPS Pharm Sci 360: Abstract Screening

SkillsSkills

People DevelopmentPeople Development

5 experiences across AstraZeneca and 1 other company5 experiences across AstraZeneca and 1 other company
Endorse

People ManagementPeople Management

4 experiences across AstraZeneca and 1 other company4 experiences across AstraZeneca and 1 other company
Endorse

TeamworkTeamwork

Off sick due to MH breadown at AstraZenecaOff sick due to MH breadown at AstraZeneca
Endorse

Show all 21 skills

PublicationsPublications

Cell surface protein aggregation triggers endocytosis to maintain plasma membrane proteostasisCell surface protein aggregation triggers endocytosis to maintain plasma membrane proteostasis
Nature Communications · Feb 28, 2023Nature Communications · Feb 28, 2023

Show publication

The ability of cells to manage consequences of exogenous proteotoxicity is key to cellular homeostasis. While a plethora of well-characterised machinery aids intracellular proteostasis, mechanisms involved in the response to denaturation of extracellular proteins remain elusive. Here we show that aggregation of protein ectodomains triggers their endocytosis via a macroendocytic route, and subsequent lysosomal degradation. Using ERBB2/HER2-specific antibodies we reveal that their cross-linking ability triggers specific and fast endocytosis of the receptor, independent of clathrin and dynamin. Upon aggregation, canonical clathrin-dependent cargoes are redirected into the aggregation-dependent endocytosis (ADE) pathway. ADE is an actin-driven process, which morphologically resembles macropinocytosis. Physical and chemical stress-induced aggregation of surface proteins also triggers ADE, facilitating their degradation in the lysosome. This study pinpoints aggregation of extracellular domains as a trigger for rapid uptake and lysosomal clearance which besides its proteostatic function has potential implications for the uptake of pathological protein aggregates and antibody-based therapies.The ability of cells to manage consequences of exogenous proteotoxicity is key to cellular homeostasis. While a plethora of well-characterised machinery aids intracellular proteostasis, mechanisms involved in the response to denaturation of extracellular proteins remain elusive. Here we show that aggregation of protein ectodomains triggers their endocytosis via a macroendocytic route, and subsequent lysosomal degradation. Using ERBB2/HER2-specific antibodies we reveal that their cross-linking ability triggers specific and fast endocytosis of the receptor, independent of clathrin and dynamin. Upon aggregation, canonical clathrin-dependent cargoes are redirected into the aggregation-dependent endocytosis (ADE) pathway. ADE is an actin-driven process, which morphologically resembles macropinocytosis. Physical and chemical stress-induced aggregation of surface proteins also triggers ADE, facilitating their degradation in the lysosome. This study pinpoints aggregation of extracellular domains as a trigger for rapid uptake and lysosomal clearance which besides its proteostatic function has potential implications for the uptake of pathological protein aggregates and antibody-based therapies.…see more

DLAB deep learning methods for structure based virtual screening of antibodies DLAB deep learning methods for structure based virtual screening of antibodies
Bioinformatics · Sep 21, 2021Bioinformatics · Sep 21, 2021
Data mining patented antibody spaceData mining patented antibody space
MAbs · Jan 12, 2021MAbs · Jan 12, 2021

Show publication

The patent literature should reflect the past 30 years of engineering efforts directed toward developing monoclonal antibody therapeutics. Such information is potentially valuable for rational antibody design. Patents, however, are designed not to convey scientific knowledge, but to provide legal protection. It is not obvious whether antibody information from patent documents, such as antibody sequences, is useful in conveying engineering know-how, rather than as a legal reference only. To assess the utility of patent data for therapeutic antibody engineering, we quantified the amount of antibody sequences in patents destined for medicinal purposes and how well they reflect the primary sequences of therapeutic antibodies in clinical use. We identified 16,526 patent families covering major jurisdictions (e.g., US Patent and Trademark Office (USPTO) and World Intellectual Property Organization) that contained antibody sequences. These families held 245,109 unique antibody chains (135,397 heavy chains and 109,712 light chains) that we compiled in our Patented Antibody Database (PAD, http://naturalantibody.com/pad). We find that antibodies make up a non-trivial proportion of all patent amino acid sequence depositions (e.g., 11% of USPTO Full Text database). Our analysis of the 16,526 families demonstrates that the volume of patent documents with antibody sequences is growing, with the majority of documents classified as containing antibodies for medicinal purposes. We further studied the 245,109 antibody chains from patent literature to reveal that they very well reflect the primary sequences of antibody therapeutics in clinical use. This suggests that the patent literature could serve as a reference for previous engineering efforts to improve rational antibody design.The patent literature should reflect the past 30 years of engineering efforts directed toward developing monoclonal antibody therapeutics. Such information is potentially valuable for rational antibody design. Patents, however, are designed not to convey scientific knowledge, but to provide legal protection. It is not obvious whether antibody information from patent documents, such as antibody sequences, is useful in conveying engineering know-how, rather than as a legal reference only. To assess the utility of patent data for therapeutic antibody engineering, we quantified the amount of antibody sequences in patents destined for medicinal purposes and how well they reflect the primary sequences of therapeutic antibodies in clinical use. We identified 16,526 patent families covering major jurisdictions (e.g., US Patent and Trademark Office (USPTO) and World Intellectual Property Organization) that contained antibody sequences. These families held 245,109 unique antibody chains (135,397 heavy chains and 109,712 light chains) that we compiled in our Patented Antibody Database (PAD, http://naturalantibody.com/pad). We find that antibodies make up a non-trivial proportion of all patent amino acid sequence depositions (e.g., 11% of USPTO Full Text database). Our analysis of the 16,526 families demonstrates that the volume of patent documents with antibody sequences is growing, with the majority of documents classified as containing antibodies for medicinal purposes. We further studied the 245,109 antibody chains from patent literature to reveal that they very well reflect the primary sequences of antibody therapeutics in clinical use. This suggests that the patent literature could serve as a reference for previous engineering efforts to improve rational antibody design.…see more

Show all 16 publications

PatentsPatents

Antibodies specific for LOX1 and use in treatment of CV disordersAntibodies specific for LOX1 and use in treatment of CV disorders
US10117889 · Issued Oct 3, 2021US10117889 · Issued Oct 3, 2021
Antibodies to ticagrelor and methods of useAntibodies to ticagrelor and methods of use
US10954308B2 · Issued Mar 23, 2021US10954308B2 · Issued Mar 23, 2021
Stabilized angiopoietin-2 antibodies and uses thereofStabilized angiopoietin-2 antibodies and uses thereof
US20170174756A1 · Issued Jul 25, 2019US20170174756A1 · Issued Jul 25, 2019

Show all 11 patents

InterestsInterests

Top VoicesTop VoicesCompaniesCompaniesGroupsGroupsNewslettersNewslettersSchoolsSchools

[Ray Dalio profile picture]
Ray DalioRay Dalio
· 3rdThird degree connection
Founder, CIO Mentor, and Member of the Bridgewater BoardFounder, CIO Mentor, and Member of the Bridgewater Board2,611,102 followers2,611,102 followers

[Bill Gates profile picture]
Bill GatesBill Gates
· 3rdThird degree connection
Co-chair, Bill & Melinda Gates FoundationCo-chair, Bill & Melinda Gates Foundation36,310,830 followers36,310,830 followers

Following

戳这里 Claim your page

来源: 文学城-TJKCB